Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.
Maddock
C
C
Landau
S
S
Barry
K
K
Maulayah
P
P
Hotopf
M
M
Cleare
A J
AJ
Norris
S
S
Pariante
C M
CM
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000139:chemically induced*; D003863:Depression / Q000139:chemically induced*; D004337:Drug Carriers / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005221:Fatigue / Q000139:chemically induced*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000523:psychology / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D012720:Severity of Illness Index; D019966:Substance-Related Disorders / Q000523:psychology; D013997:Time Factors; D016896:Treatment Outcome
D000998:Antiviral Agents; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b